IL33 and breast cancer: In particular, the implication of IL-33 acting as a “danger” signal in tumor-associated inflammation has been reported in multiple cancers, including breast cancer, gastric cancer, head and neck cancer, lung cancer, and hepatocellular carcinoma [76,77,78,79,80].